January 2020
The emerging role of magnetic resonance in the detection of chronically significant prostate cancer, Pamela Coleman, MD 1/28/20
The evolving Gleason grading system.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4779758/
In patients with a previous negative prostate biopsy and a suspicious lesion on magnetic resonance imaging, is a 12-core biopsy still necessary in addition to a targeted biopsy?
https://onlinelibrary.wiley.com/doi/epdf/10.1111/bju.12938
Accuracy of Magnetic Resonance Imaging/Ultrasound Fusion Targeted Biopsies to Diagnose Clinically Significant Prostate Cancer in Enlarged Compared to Smaller Prostates.
Multiparametric magnetic resonance imaging and ultrasound fusion biopsy detect prostate cancer in patients with prior negative transrectal ultrasound biopsies.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3895467/
Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4572575/
Multiparametric magnetic resonance imaging (MRI) and subsequent MRI/ultrasonography fusion-guided biopsy increase the detection of anteriorly located prostate cancers.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5613950/
Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings.
https://www.auajournals.org/doi/10.1016/j.juro.2006.08.007
Multiparametric 3T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds.
https://www.auajournals.org/doi/10.1016/j.juro.2011.07.013
Is repeat prostate biopsy associated with a greater risk of hospitalization? Data from SEER-Medicare.
https://www.auajournals.org/doi/10.1016/j.juro.2012.10.005
Epidemiology of Prostate Cancer.
